INTRODUCTION
Trimetazidine Dihydrochloride is chemically described as 1-(2, 3, 4-trimetho xybenzyl) piperazine. It is an energy metabolism of the cell exposed to hypoxia or ischemic, avoids the collapse of the intracellular level of adenosine triphosphate (ATP). It thus ensures the functioning of the ion pumps and the transmembrane flow of sodiumpotassium and maintains cellular homeostasis. It has been used in the form of its Dihydrochloride as a coronary vasodilator for the prophylactic treatment of angina pectoris crisis, its short biological half life (6 h ) that calls for frequent daily dosing (2 to 3 times) and therapeutic use in angina pectoris crisis disease necessitates its formulat ion into modified release dosage form 1 . The development of Modified / Controlled release formulat ion of Trimetazidine Dihydrochloride is therefore of therapeutic relevance and can be used to provide a consistent dosage through sustaining an appropriate level o f drug over time. The simp lest and least expensive way to control the release of the drug is to disperse it within an inert polymeric matrix and hydrophilic matrices are an interesting option when formulat ing an oral modified release (M R) of a drug. The dosage release properties of matrix devices may be dependent upon solubility of the drug in the polymer matrix or, in case of porous matrices, the solubility in the sink solution within the particle's pore network. Hydro xypropylmethylcellulose (HPM C) is the dominant hydrophilic vehicle used for the preparation of oral controlled drug delivery systems 3 . Numerous studied have been reported in literature investigating the HPMC matrices to control the release of a variety of drugs from matrices. The objective of the present study was to formulate Trimetazidine Dihydrochloride MR Matrix tablets using HPMC K4M poly mer and to elucidate the release kinetics of Trimetazidine Dihydrochloride fro m HPM C matrices. We attempted a systematic approach to develop twice daily modified release Trimetazidine Dihydrochloride matrix tablets.
MATERIALS AND METHODS
Trimetazidine Dihydrochloride was obtained from MJ BIOPHA RM Pvt ltd, Mumbai, HPMC K4M, a grade of HPM C, was procured fro m MJ BIOPHA RM Pvt ltd, Mumbai, Dibasic Calciu m Phosphate (Anhydrous), was procured from MJ BIOPHARM Pvt ltd, Mumbai., Polyvinyl Pyrrolidone (PVP-K30), Aerosil R 200 and Magnesium Stearate, was procured fro m MJ BIOPHARM Pvt ltd, Mumbai, Isopropyl Alcohol was procured from Rankem, Delhi. Materials and excipients used in preparing tablets were IP grades. All other ingredients used throughout the study were of analytical grade and were used as received.
Preparati on of matri x tablets:
Matrix tablets, each containing 35.3 mg Trimetazidine Dihydrochloride, were prepared by wet granulation technique. The drug polymer concentration was developed to adjust drug release and to keep total weight of tablet constant for all the fabricated batches under experimental conditions of preparations. The total weight of the matrix tablets was 200 mg with different drug polymer (HPM C) concentration. A batch of 1000 tablets was prepared in each formula. The composition of tablets is shown in Table 1 . Dibasic calciu m phosphate (anhydrous) was incorporated as filler excipient to maintain tablet weight constant. This filler was incorporated also for counterbalance the faster solubility of the drug in presence of hydrophilic poly mer and to provide a stable monolithic matrix. The ingredients Trimetazid ine Dihydrochloride, HPM C, Dibasic calciu m phosphate (anhydrous) were passed through sieve no. 40 and mixed in a polybag. The powder blend was granulated using granulating fluid PVP-
ABS TRACT
M onolithic matrix tablets of Trimetazidine Dihydrochloride were formulated as modified release tablet employing hydroxyl propyl methyl cellulose polymer, and the modified release behaviour of fabricated tablets was investigated. M odified release matrix tablets contain 35.3 mg Trimetazidine Dihydrochloride were developed using different drug polymer concentration of H.P.M .C. Tablets were prepared by wet granulation using I.P.A. Formulation was optimized on the basis of acceptable tablet properties and in vitro drug release. The resulting formulation produced robust tablets with optimum hardness, consistent weight uniformity and low friability. All tablets but one exhibited gradual and near-completion modified release for Trimetazidine Dihydrochloride, and 98.5 to 101.5% released at the end of 12 h. The results of dissolution studies indicated that formulation F-III, the most successful of the study. An increase in release kinetics of the drug was observed on decreasing polymer concentration. 
Evaluati on of tablets:
The prepared mat rix tablets were evaluated for hardness, weight variat ion, thickness, friability and drug content.
Hardness of the tablets was tested using a strong-cobb hardness tester (Tab machine, Mu mbai). Friability of the tablets was determined in a Roche friabilator (Campbell Electronics, Mumbai). The thickness of the tablets was measured by vernier callipers. Weight variation test was performed according to official method 9. Drug content for Trimetazidine Dihydrochloride was carried out by measuring the absorbance of samples at 231 n m using Shimad zu 1201 UV/ Vis spectrophotometer and comparing the drug content from a calibrated curve prepared with standard Trimetazidine Dihydrochloride in the same med iu m.
In vi tro drug release studies:
The in vitro dissolution studied was carried out using USP 24 dissolution apparatus type II [10] (Basket method) at 50 rpm. Dissolution test was carried out for a total period of 12 h using 0.1N HCl (pH 1.2) solution (900 ml) as dissolution mediu m at 37 ± 0.50 for 1 hr, and pH 6.8 phosphate buffer solution (900 ml) minimu m of 2 hrs. Ten millilitres of the sample was withdrawn at regular intervals and replace with the same volume pre-warm (37 ± 0.50) fresh dissolution med iu m. The samples withdrawn were filtered through 0.45µ membrane filter, and drug content in each sample was analyzed after suitable dilution by abovementioned spectrophotometer at 231 nm. The actual content in samples was read from a calibration curve prepared with standard Trimetazid ine Dihydrochloride.
Stability studies:
One selected fabricated tablet batch was strip packaged and kept at 400°c with 75%RH. Samp les were withdrawn at 30 and 60 °c for evaluation of appearance, drug content and in vitro drug release.
RES ULT AND DISCUSSION
The result of hardness and friability of the prepared matrix tablets ranged from 7.0 to 8.5 and 0.12 to 0.31 respectively. (Table 3 ). The tablet formu lations in all the prepared batches contained Trimetazidine Dihydrochloride within 100 ± 5% of labelled content. As such, all the batches of the fabricated tablets were of good quality with regard to hardness, friability and drug content. All tablets complied with pharmacopoeial specifications for weight variation and friability. Trimetazid ine Dihydrochloride release fro m tablets was slow and extended over longer periods of time. The results of dissolution studies of formulat ions F-I to F-V are shown in fig. 1 . Drug release fro m the mat rix tablets was found to increase with decrease in drug polymer concentration. Formulat ion F-I and F-II composed of drug concentration release to sustained release after 12 h. The release of drug depends not only on the nature of matrix but also the drug polymer concentration. As the percentage of polymer increased, the kinetics of release decreased. This may be due to structural reorganization of hydrophilic HPM C poly mer. Increase in concentration of HPM C may result in increase in the tortuosity or gel strength of the polymer. When HPM C poly mer is exposed to aqueous mediu m, it undergoes rapid hydration and chain relaxation to form v iscous gelatinous layer (gel layer). Failure to generate a uniform and coherent gel may cause slow drug release [11, 12] . In vitro release studies demonstrated that the release of Trimetazidine Dihydrochloride fro m all these formulated MR mat rix tablets can generally be modified ( fig. 1 ). According to commercial tablet, modified release profile of oral controlled release formu lation of Trimetazidine Dihydrochloride should provide a release of 25-45% in 1 h, 43-63% in 2 h, NLT 60% in 4 h and NLT 80% in 8 h.
Formulat ion F-III tablet gave release profile close to the commercial mod ified release tablet needed for Trimetazidine Dihydrochloride ( fig. 1 ). The data for stability studies carried out for F-III batch at 400°c with 75% RH for 60 d revealed that no considerable differences in drug content and dissolution rate were observed (Table  4) . It may be concluded from the present study that slow, controlled and complete release of Trimetazidine Dihydrochloride over a period of 12 h was obtained from matrix tablets (F-III). It is also evident from the results that formulat ion F-III is better system for twice-daily MR of Trimetazidine Dihydrochloride. 
CONCLUS ION
In the above view of findings it can be concluded that the combination of hydrophobic polymer and pH dependent polymer are better suited for site specific drug delivery system than hydrophobic polymer alone. A matrix design of this kind can serve as an alternative strategy to enteric film coating techniques commonly employed for the design of delayed release systems.
